European Society for Medical Oncology (ESMO) Congress 2025
17 October - 21 October, 2025, Germany
Final overall survival (OS) data analysis from the phase III ALEX study presented at ESMO 2025 indicates alectinib is superior to crizotinib in patients with previously untreated ALK-positive (ALK+) non-small-cell lung cancer (NSCLC).